Circulating blood must remain fluid: if it does not, the culminating thrombosis is a pathological event with definable sequelae. It is unlikely, on teleological grounds, that such a defensive mechanism should exist only in moments of peril. Hence a general if tacit assumption has developed that clotting is not an episodic but a continuous process (Macfarlane, 1945; Roos, 1957) which normally is never allowed to progress to a physical end-point unless vascular integrity is in jeopardy. But if the maintenance of fluidity, in circumstances which permit the possibility of clotting, is a physiological necessity, then one must conceive a homeostatic system in which equilibrium is maintained by the balance of equal yet opposing forces (Astrup, 1962) . It is in this context of a continuous physiological requirement, as distinct from episodic pathological changes, that fibrinolysis must bejudged. Moreover, we are dealing with a biological system dependent upon protein 'activity' which can be expressed only as a resultant of these balanced opposing forces: the function of single protein moieties cannot be measured in isolation.
It is important to appreciate that haemostasis is governed, also, by the effects of both time and motion: in physiology, the persistence of free flow must directly influence the sequence of events.
Study in vitro can never simulate the interplay of forces engaged in this endless yet beneficial conflict. There is one further point to be borne in mind, intravascular thrombosis in pathology is primarily a venous phenomenon with occlusive effects on a moving stream, whereas the minor wear-and-tear thrombotic episodes acknowledged to be incidental to everyday life occur largely in the capillary bed, parts of which, intermittently, may be shunted out of the general circulation and thus become stagnant.
The physiological significance of fibrinogen appears to depend solely on its polymerization to fibrin followed by gelation and subsequent condensation (clot retraction). This chain reaction is governed, and the fluidity of blood maintained, by two proteolytic enzymes acting in opposition, thrombin and plasmin, each derived from a naturally circulating plasma precursor prothrombin or plasminogen ( Figure 1) .
Study of the clinical effects of enhanced polymerization is relatively simple because a clot can be seen and felt. The opposite is not so, for fibrinogenolysis in vivo (degradation of fibrinogen while still in solution in contrast to destruction of fibrin) can only be assessed in terms of haemostatic failure: minimal enhancement is probably a natural event for which there is some evidence of diurnal variation (Fearnley, Balmforth, and Fearnley, 1957) (Madden and Gould, 1952; Hammond and Verel, 1959) and somewhat less in dogs (Lewis, Ferguson, and Schoenfeld, 1961) and rabbits (Cohen, Holloway, Matthews, and McFarlane, 1956) . This method of assessment may not be valid, however, as isotopic labelling of fibrinogen and its re-introduction into the blood stream demonstrably leads to sequestration: moreover, Lewis et al. (1961) have shown that systemic administration of coumarin or heparin does not prolong the half-life although manifestly altering intrinsic coagulation sequences.
THE VASCULAR MILIEU
Whilst it is convenient to discuss fibrinolysis or coagulation as apparently distinct processes, it is axiomatic that the physiological significance of the one mechanism can be judged only in terms of the other: and any apparent pathological enhancement of either mechanism must also be viewed in the possible context of simultaneous retardation of the other. Figure 2 shows that each intrinsic system is governed by the interaction of globulins in biological solution and these, in turn, are influenced by their relative molecular concentration and their proximity to metallic ions and to cell and vessel surfaces. In certain circumstances, to these features must be added the effect of flow rate and, should fibrinogen ever polymerize, the apparently specific yet selective attraction of the surface so formed for some of the moieties taking part, whereby their local effect is concentrated. (Lorand, 1961; Laki, 1962) is sufficiently Macfarlane (1964) likens the sequential generation at plasminogen of thromboplastin and prothrombin-thrombin conrmed, in the version to a radio amplifier circuit. Using this ibably, may be analogy, the transitory accumulation of peptide irrent methods by-products may serve to check or limit the reaction as a whole, on the principle of negative feed-back. Thus some of the functions loosely termed anti-)nLYSIS Some thrombin or anti-plasmin result from the reactioñ n and fibrino-which they serve to restrict. Environmental features may thus be disturbed. As this biological phenomenon occurs in the vascular bed, it is relevant to note that contact factors are associated with those SURFACE STIMUL&TION governing vascularpermeability (Spector, 1957; Marlco golis, 1958a and b; Mill, Elder, Miles, and Wilhelm, ACTIVATOR GENERATION 1958) and pain (Keele, 1957) and with bradykinin 10. (Lewis, 1962) whilst the negatively charged fibrino-PRSOTEOLYTIC CONVERSION peptides may influence the migration of leucocytes )FTO IIVE.MCURR (Sawyer and Pate, 1953) and fibrin lysates may antagonize histamine (Copley, 1962 (Fearnley, 1953; Sawyer, Fletcher, Alkjaersig, and Sherry, 1960) , but this is so readily released from blood vessel walls after relatively trivial stress that it is difficult to be certain. Nor is it yet known whether all plasminogen activation follows a similar sequence in man. Physical exercise and adrenaline injection (Biggs, Macfarlane, and Pilling, 1947) , emotional or traumatic shock (Macfarlane and Biggs, 1946) , and the administration of pyrogens or drugs, such as nicotinic acid, which act on vessel walls, will each release activator into the plasma. The principal site for plasma activator formation appears to be the vessel wall itself (Kwaan, Lo, and McFadzean, 1957; Todd, 1959) but other forms of plasminogen activator are found in almost all body tissues and secretions (Astrup and Permin, 1947; Albrechtsen, 1957) with the possible exception of liver where plasminogen itself is elaborated. Urokinase, found in normal urine (Williams, 1951) , is the form most readily available for study and, as it appears in equal amounts in the bladder and the renal pelvis, there is speculation about its origin from the blood stream or from functioning kidney tissue. The high concentration of activator in prostatic and lung tissue can become clinically significant if these are roughly handled during operation.
OTHER ACTIVATORS In addition to naturally occurring factors, artificial activators have been studied. Some, such as chloroform (Tagnon, 1942) , achieve this effect by reducing antiplasmin activity. The bacterial extract, streptokinase, from the haemolytic streptococcus, was the first to be introduced (Tillett and Garner, 1933) and is of clinical importance because it can now be given intravenously. Of bovine substrates, streptokinase seems to require a co-factor, pro-activator, before it can convert plasminogen: this may also be true in the human or, in this instance, plasminogen may be capable of serving in both roles (Ablondi and Hagan, 1957; Kline, 1960 and Flute (1960) clearly demonstrated that its apparent lability, as shown by Fearnley and Lackner (1955) , is due to the rise in the function of anti-activator rather than to any reduction in activator activity. Careful avoidance of contact with wettable surfaces and a rigidly applied cold technique, during which the plasma sample is retained between 0 and 40C., reduce the development of anti-activator function to a minimum. PLASMINOGEN This is a naturally circulating inactive beta-globulin with a molecular weight which may be as high as 140,000 (Shulman, Alkjaersig, and Sherry, 1958) or as low as 83,800 (Davies and Englert, 1960) . Sgouris, Inman, McCall, Hyndman, and Anderson (1960) have described a technique for its preparation from the Cohn fraction III paste usually discarded in the preparation of gamma globulin from outdated blood (Oncley, Melin, Richert, Cameron, and Gross, 1949) . It is stable in plasma and comes down with the 'euglobulin' fraction after dilution with acidified distilled water: the plasma euglobulin fraction or the fibrinogenfree serum euglobulin fraction can thus be utilized to provide a convenient laboratory source (Howell, 1963; Hawkey and Stafford, 1964) .
The plasminogen molecule is probably larger than plasmin (Shulman et al., 1958) , and there is thus a direct analogy with the relation in size of prothrombin to thrombin and of fibrinogen to fibrin. The conversion of plasminogen to plasmin appears to involve the removal of a moiety so laying bare a centre of activity: as in other biological systems a relatively small alteration in configuration may radically change protein function. Kline (1960) is convinced that the proactivator necessary in the streptokinase reaction is plasminogen in another guise, in which either two active centres are uncovered or a different surface radicle is exposed so that two separate reactions may occur.
Plasminogen may have a specific affinity for fibrin (Back, Ambrus, and Markus, 1959) whereby it can be adsorbed to the fibrin surface; it may be, however, that it is the activator factors which alone possess this affinity. The fact that one or both can be concentrated by specific attraction to fibrin surfaces leads to the ready conversion of plasmin at the site where it is required yet with minimum influence from anti-plasmins.
PLASMIN In vitro this proteolytic enzyme has substrate specificity for both fibrinogen and fibrin (Ratnoff, 1953;  Ambrus and Markus, 1960) : it will also digest certain protein components of the coagulation system-factor V, factor VIII (antihaemophilic), and prothrombin (Fletcher, Alkjaersig and Sherry, 1959; Donaldson, 1960; McNicol, Douglas, and Bayley, 1962) . Its digestion of casein permits comparative measurement of activity, but as this is scarcely physiological, many different methods have been devised to assess the lysis of fibrin itself under controlled conditions. Such laboratory methods are based either on external visible lysis of a fibrin plate (Astrup and Mullertz, 1952) when the proteolytic enzyme is added from outside, or on internal lysis promoted by incorporating the fibrinolytic agent within the clot itself. In the latter, the breakdown of 1311-fibrinogen can be measured by the iodine released (Shulman and Tagnon, 1950; Clement and McNicol, 1959) or a standardized clot (Christensen, 1949) , containing red cells (Blix, 1962; Howell, 1964a) , can be formed with standardized substrates: this approach at least simulates the spatial relationship between the various interacting components and the end-point can be judged as the time taken for total lysis (Hawkey and Stafford, 1964) .
Plasmin apparently digests fibrinogen by hydrolysis of peptide bonds as arginine and lysine residues: synthetic substrates containing esters of these aminoacids may act as competitive inhibitors (Troll, Sherry, and Wachman, 1954 (Norman, 1958; Fletcher et al., 1959) ; this is relevant to any discussion of a dynamic equilibrium. Such inhibitory mechanisms may also have a beneficial tendency to restrict plasmin to its digestion of fibrin. At least two antiplasmin plasma proteins exist: an alpha 1 globulin and a more rapidly acting alpha 2 globulin (Norman and Hill, 1958) . Platelets also exert antiplasmin activity.
The reactions with plasmin of these circulating inhibitors are markedly affected if the protein substrate, fibrin, is present. This is because fibrin is more avid for the active site on plasmin than is anti-plasmin: conversely fibrinogen, although also a substrate, seems to be less avid (Celander and Guest, 1957) . Thus a homeostatic bias promotes the destruction of fibrin but permits the preservation of fibrinogen.
The three-dimensional significance of the surface provided by formed fibrin is the basis for an attract-ive hypothesis introduced by Sherry and his colleagues to explain the physiological mechanism involved in clot destruction or thrombolysis (Sherry, Fletcher, and Alkjaersig, 1959a; Sherry, Lindemeyer, Fletcher, and Alkjaersig, 1959b) . In the interstices of thrombi, because of the physical affinity of plasminogen for fibrin, the local concentration of plasminogen is relatively high whilst that of antiplasmin is relatively low, unless there is a pathological excess of platelets. Thus, when circulating plasma activator diffuses into an area of thrombosis, the intrinsic clot plasminogen is activated and the resultant plasmin, unimpeded by antiplasmin, is readily able to digest its fibrin substrate. Any diffusion of plasmin back into the general circulation is relatively innocuous because plasma antiplasmins serve to protect fibrinogen in solution.
The difficulty of distinguishing between activation of one factor and the inhibition of its antagonist has led to somewhat complex explanations of what may be a relatively simple interplay of plasma proteins. This difficulty is most apparent when protein interaction is related to adjacent non-protein components: ionic calcium classically enhances coagulation yet Fearnley (1961) has reported it to inhibit fibrinolysis. Bruce (1964) has shown, however, that calcium probably influences plasmin function by activating the antiplasmin inhibitors.
THE PHYSICAL CHARACTER OF FIBRIN
Whatever might be thought of the physiological role played by plasmin the topic is not readily amenable to scientific proof: most of the current knowledge of fibrinolysis has been gleaned from observed pathology, when either coagulation or fibrinolysis has established hegemony over the other.
In pathological states of venous or arterial thrombosis the adsorptive capacity of the fibrin surface is apparently decisive: furthermore, the coincidence of endothelial abnormality or the consequence of occlusion results in a changed flow pattern. In these circumstances the interplay of protein moieties is conditioned by features which are absent from normal physiology. At this point in discussion it is thus necessary to consider the physical qualities of the fibrinogen molecule and of its polymer (Scheraga, 1958) .
Reference to the work of Hall and Slayter (1959) and to the many papers by Laki (1951 Laki ( , 1962 and by Lorand (1961) The surface attraction of these moieties is depicted in relation to a broad band of fibrin molecules polymerized by side-to-side bonding ( Figure 5 ). Ionic calcium, platelets, and the serum globulin 'fibrin-stabilizing factor (fsf)' seem to enjoy some special relationship denied to the other circulating factors. The fibrin-stabilizing factor, now known as factor XIII, serves in the process of conversion of the early monomeric fibrin molecule, which is urea-soluble, to the urea-insoluble polymer capable of clot retraction. Calcium may promote additional linkages between factor XIII and these fibrin molecules, rendering them less susceptible to attack by plasmin (Bickford and Sokolow, 1961) .
In the normal course of events, the fibrin monomers will condense to form fibrin polymer, assuming that sufficient thrombin is present. Excess free plasmin, if it is in sufficient concentration to nullify the inhibitory power of the antiplasmins, will attack fibrinogen as well as fibrin, and the polypeptide fragments so formed can physically interfere with any polymerization taking place in the immediate vicinity. The polypeptide fragment or breakdown product becomes incorporated within the polymer but, as it lacks correct configuration, the resultant clot is friable and subsequent clot retraction is defective. Bang, Fletcher, Alkjaersig, and Sherry (1962) have studied the electron microscopic features of this defective fibrin mesh. Excessive accumulation of these relatively large breakdown moieties may ultimately block further polymerization, and indeed, may also provoke haemorrhagic episodes by their effect on the vascular endothelium , a point to be borne in mind during the phase of excessive intravascular fibrinolysis induced by thrombolytic therapy (Flute, 1964) . To this, thrombin and activator are specifically adsorbed: plasminogen and the fibrin stabilizing factor (fsf) may also be attracted. Antiplasmins may be trapped within the clot mesh and thus inhibit plasminogen conversion; the by-products, fibrinopeptides and fibrin lysate polypeptides, may also have a retarding influence. Calcium may have a cardinal role of enhancing thrombin and antiplasmin activity, and serving as a cationic bridge for other protein linkages.
turbulence engendered by arterial pulsation or the eddying where veins receive tributaries: only in capillaries is laminar flow likely to be constant, and in vessels of such small calibre the actual distribution of cell particles is subject to the sigma phenomenon (Scott-Blair, 1958) whereby blood alters its apparent viscosity with changing conditions of flow. Copley (1953 Copley ( , 1962 discusses the significance of laminar flow and its production of a relatively immobile outer, intimal, zone of plasma which at its extreme edge may present a single line offibrinogen molecules. At one time Copley suggested that fibrin itself might be directly opposed to the vessel wall but this has not attracted credence.
Possibly there are two fields of action for the depredations of thrombin and plasmin. In the capillary bed a protracted physiological form of guerrilla skirmishing is dominated by plasmin: here the permeability of the endothelial barrier to encroachment by tissue moieties, the intermittent nature of flow in alternately functioning or stagnant networks, and the relatively greater proportion of plasma to cells induced by the sigma effect may provide an environment optimally designed to cope with the myriad but minor breaches of vascular integrity-'wear-and-tear'. In the venous or arterial streams, however, which should not normally be stagnant, the greater flow rate, larger proportion of cells to plasma, and the different nature of the vessel walls, allow only isolated forays which, as they are induced by pathological changes, may result in a local ascendency of thrombin over plasminpolymerization of fibrinogen rather than its lytic destruction. Especially might this be so if inflammation of the vein wall or atherosclerotic changes in the arterial intima provide focal points for the aggregation of platelets.
One might speculate further that the essential difference between these two intravascular fields of action is emphasized during the process of ageing: with senescence, capillary fragility and its attendant bleeding contrasts with the occlusive tendency in larger vessels. This does not necessarily conflict with the morphological concept underlying 'fibrinous vasculosis' (Lendrum, 1955 (Lendrum, , 1963 for this is based on extravascular escape of plasma molecules. Clearly the equilibrium between fibrinolysis and coagulation in the tissues must be governed by different laws, and the fate suffered by the fibrinogen molecule can scarcely be comparable. The exercise in semantics involving the word 'fibrinoid' (Pagel 1951; Movat and More, 1957; Lendrum, Fraser, Slidders, and Henderson, 1962) (Albrechtsen, 1957) and that in milk (Astrup and Sterndorff, 1953), saliva (Albrechtsen and Thaysen, 1955) , and tears (Storm, 1955) . Von Kaulla (1963) speculates upon the importance of interaction between components of the fibrinolytic system in the process of fertilization, as seminal fluid contains plasminogen activator (von Kaulla and Shettles, 1953) . The significance of lysis within the lymph system, which contains a substantial proportion of the body fibrinogen pool, has not yet been assessed, but in the joint cavities Lack (1963) has made a close study of the importance of fibrinolysis in relation to joint function and synovial integrity.
LOCAL FEATURES
The dynamic equilibrium between coagulation and fibrinolysis allows the clotting system to correct endothelial defects with a haemostatic fibrin seal while the fibrinolytic system prevents further progress to occlusion by removing any fibrin scaffolding once the endothelium is repaired.
There remain three local features which must be brought into any consideration of the fibrinolytic maintenance of vascular patency: the nature and function of endothelium (Altschul, 1954; Warren, 1964) , the part played by platelets (Holemans and Gross, 1961) , and the presence of proteins other than those directly involved in haemostasis, chylomicrons and low-density lipoproteins (Greig, 1956; Pappenhagen, Kopel, and Olwin, 1963; Howell, 1964a and b) .
THE ENDOTHELIUM Albrechtsen (1957) and Todd (1959) have shown plasminogen activator activity in the intact vessel wall, and Warren (1963) has clearly demonstrated this to be present in isolated endothelial cells themselves. In his review of endothelial ultrastructure, Palade (1961) stresses the physiological necessity for an ample and continuous exchange across the capillary wall between plasma and interstitial fluid. In this context this implies movement inwards of plasminogen activator and the reverse flow of degradation products, fibrin monomer, or the partially polymerized fibrinogen referred to by Copley (1962) . An earlier belief in mural pores has been superseded by the electron microscopic demonstration of sack-like calveolae intracellulares which open onto the cell surface or move across the cytoplasm. Any such carrier structure bears a resemblance to the lysosome (de Duve, 1963) and may thus be related to the activity of intracellular acid hydrolases. Lack (1963) has demonstrated that certain lysosomes contain plasminogen activator, 7 a finding which may be equated with the plasminogen activator properties of disintegrated leucocytes reported by Gans (1964) and long recognized in abscess formation. Endothelial lysosomes, if they exist, by being particularly susceptible to local hypoxia or damage, might actively contribute to the induction of capillary permeability (Miles and Wilhelm, 1960) .
Plasma kinins, which evoke pain, are released into the plasma after surface contact stimulation (Armstrong, Jepson, Keele, and Stewart, 1957) . One of these, kallikrein, is an active form of an inactive plasma precursor, kallikreinogen, which is similar in many respects to plasminogen. Kallikrein may be an enzyme which is quite distinct from plasmin, or it might be this latter moiety after it has been modified by some inhibitor or activator, consequent upon contact; its formation is thus intimately concerned with factor XII. Kallikrein differs from plasmin as it does not attack casein or fibrin, nor is it inhibited by epsilon aminocaproic acid (Eisen, 1963) . One might speculate upon the relationship between the normal endothelial surface, the contact factors, plasma kinins, and permeability factors: but there is little objective physiological evidence upon which to base this conjecture.
PLATELETS The effect of fibrinolysis on these cell fragments depends on whether they are intact, when their surface adsorptive qualities may contribute calcium ions and certain protein molecules, or disrupted. Their being intact will also influence fibrinolysis according to whether they remain discrete and mobile, or become sticky, undergo viscous metamorphosis and clump.
Their function should only be assessed having regard to their simultaneous involvement in clotting and in clot retraction. Johnson and Schneider (1953) first showed platelets to contain an antiplasmin, inhibiting fibrinolysis. Bierstedt (1958) found isolated intact platelets to possess an opposite, accelerating, effect which Holemans and Gross (1961) believe to be due to surface adsorption of a proactivator which they differentiate from plasminogen activator.
Platelets do not carry or contain measurable plasminogen but during the phenomenon of clumping they may become intimately linked with fibrinogen--'platelet fibrinogen' (Johnson, Smathers, and Schneider, 1952) . Electron microscopy of artificially induced platelet aggregates (Poole, 1959) and platelet thrombi (Poole, French, and Cliff, 1963; Rodman, Mason, and Brinkhous, 1963) does not necessarily show fibrin to be present between adjacent cell margins, and their agglomeration in the so-called 'white bodies' occasionally seen to circulate in physiological circumstances still requires explanation. Johnson and McKenna (1963) have shown that the clotting of relatively low platelet concentrations forms a coarse fibrin network, whilst very high platelet concentrations form significantly less fibrin without clot retraction.
The role of platelets in the lysis of formed thrombi is plainly different from any function they may serve in the moving plasma stream.
LIPOPROTEINS In vitro, low-density lipoproteins, chylomicron suspensions, and phospholipid preparations may, in certain circumstances, inhibit fibrinolysis; and, in vivo, the prolongation of the clot lysis time has been observed by several workers after alimentary hyperlipaemia has been induced by saturated fats. Whether this is merely a function of surface adsorption, or whether electro-negative lipid moieties physically interfere with the contact between interacting protein molecules, has yet to be explicated. The demonstration of these effects of plasma lipids has led to speculation about the relation between inhibited physiological fibrinolysis and the incidence of atherosclerosis: among others, Merskey, Gordon, and Lackner (1960) and Howell (1964b) have shown a somewhat greater fibrinolytic potential in the Negro as compared with European controls, and attention has thus been focused on possible racial differences in plasma lipid components or their concentrations, and on the incidence of myocardial ischaemia. The epidemiological or sociological implications of these findings lie more in the province of atherosclerosis research but the subject, as it relates to fibrinolysis, has been reviewed recently by Howell (1964b 
